Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic bone marrow or peripheral blood stem cells
- Development stage
- Unknown
- Lead developer
- St. Anna Children's Cancer Research Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic bone marrow or peripheral blood stem cells are used as a therapeutic intervention in hematopoietic stem cell transplantation (HSCT) for patients with chronic myeloid leukemia (CML). In the context of the RIC Allo-SCT for Pediatric CML trial conducted by St. Anna Kinderkrebsforschung, these cells are administered following a reduced intensity conditioning (RIC) regimen consisting of fludarabine, melphalan, thiotepa, and anti-thymocyte globulin (ATG). The goal of the transplant is to replace the patient's diseased bone marrow with healthy donor stem cells, potentially offering a curative alternative to lifelong tyrosine kinase inhibitor (TKI) therapy. The protocol includes post-transplant monitoring and potential donor lymphocyte infusions (DLI) to manage residual disease.
- Other names
- bone marrow or peripheral blood stem cells-St. Anna Kinderkrebsforschung-chronic myeloid leukemiaallogeneic hematopoietic stem cellsbone marrow or peripheral blood stem cells
Beyond the preview
Go deeper on allogeneic bone marrow or peripheral blood stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic bone marrow or peripheral blood stem cells.